DBV Technologies SA – American ( (DBVT) ) has shared an announcement.
On March 27, 2025, DBV Technologies announced a private placement agreement to raise up to $306.9 million (€284.5 million) to advance its Viaskin Peanut program. The financing, led by prominent healthcare investors, will support the company’s efforts to submit a Biologics License Application to the FDA and prepare for a potential U.S. launch. The funding will result in a dilution of existing shareholders but reflects strong investor confidence in the Viaskin Peanut patch’s potential impact on treating pediatric peanut allergies.
More about DBV Technologies SA – American
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric allergies. Its primary product is the Viaskin Peanut patch, which is designed to treat peanut allergies in children. The company is working towards the commercialization of this product, particularly in the U.S. market, pending regulatory approval.
YTD Price Performance: 90.77%
Average Trading Volume: 431,951
Technical Sentiment Signal: Buy
Current Market Cap: $120.2M
See more insights into DBVT stock on TipRanks’ Stock Analysis page.